A Phase II Study of Neoadjuvant rFowlpox-PSA (L155)-TRICOM (Prostvac-F/TRICOM) in Combination With rVaccinia-PSA (L155)-TRICOM (Prostvac-V/TRICOM) in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Rilimogene galvacirepvec (Primary) ; Rilimogene glafolivec (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 17 Jan 2018 Status changed from active, no longer recruiting to completed.
- 25 Aug 2017 Planned End Date changed from 1 Oct 2017 to 31 Jan 2018.
- 25 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 31 Jan 2018.